Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling

Glucagon-like peptide-1 (GLP-1) therapies are routinely used for glycaemic control in diabetes and their emerging cardiovascular actions have been a major recent research focus. In addition to GLP-1 receptor a...

Source: Cardiovascular Diabetology - April 14, 2016 Category: Cardiology Authors: Emma Robinson, Mitchel Tate, Samuel Lockhart, Claire McPeake, Karla M. O’Neill, Kevin S. Edgar, Danielle Calderwood, Brian D. Green, Barbara J. McDermott and David J. Grieve Source Type: research